You are here

A Microfluidic Impedance-Based Bacteriophage Capture and Antibiofilm Analyzer

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH21P0020
Agency Tracking Number: H20B-003-0025
Amount: $249,996.51
Phase: Phase I
Program: STTR
Solicitation Topic Code: DHA20B-003
Solicitation Number: 20.B
Solicitation Year: 2020
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-02-01
Award End Date (Contract End Date): 2021-08-31
Small Business Information
6820 Moquin Dr NW
Huntsville, AL 35806-2900
United States
DUNS: 185169620
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Deborah Ramsey
 (256) 726-4909
Business Contact
 Evan Richardson
Phone: (256) 361-0801
Research Institution
 San Diego State University
 Jennie Amison
5500 Campanile Dr
San Diego, CA 92120-9212
United States

 (619) 594-5731
 Nonprofit College or University

The twenty-first century has seen a global rise in bacterial infections exhibiting antimicrobial-resistance (AMR). More than ninety percent of chronic wounds contain microbial biofilms that exhibit AMR, and the bacteria responsible for several of these recalcitrant infections are called ESKAPEE pathogens. Eradicating ESKAPEE pathogenic infections is challenging, but bacteriophage (phage) therapy is emerging as a new tool to combat AMR in biofilms. Phages thrive in nature, but phage isolation and cultivation from environmental samples requires expensive instrumentation and trained operators. In order to streamline the rapid identification and isolation of phages, we propose to develop a microfluidic impedance-based bacteriophage capture and antibiofilm analyzer (MIPACAA). The portable analyzer will use interchangeable, micro-scale biofilms to capture and enrich phages with antibiofilm activity from environmental samples. During Phase I, we will develop an impedance-based microfluidic biofilm platform for two ESKAPEE pathogens and measure biofilm biomass reduction due to phage infection. Phase II research will focus on development and characterization of an alpha prototype for the handheld, ruggedized analyzer that can be used in the field. The developed micro-biofilm capture and storage platform with antibiofilm activity analysis will provide a robust and cost-saving system for evaluating environmentally-sourced phages that are effective against ESKAPEE pathogens.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government